Rokit Healthcare to Begin Human Clinical Surgery for Kidney Regeneration Using 3D Bioprinting in July

Rokit Healthcare announced on June 12, 2026, at the Korean Society of Nephrology academic conference that it has received approval for an advanced regenerative medicine clinical trial and will commence human clinical surgery in July. The procedure uses an AI-driven 3D bioprinting platform combined with robotic surgery to create an autologous omentum-derived cell patch for kidney regeneration. The initial phase will evaluate safety and regenerative potential, following preclinical and large-animal studies that demonstrated feasibility. The company plans to pursue regulatory approval for advanced regenerative medicine therapy in the fourth quarter of 2026.

This milestone places Rokit Healthcare among a very small group of firms attempting to translate bioprinting from tissue engineering research into actual therapeutic intervention. While bioprinting has advanced in academic labs for years, clinical adoption remains extremely rare due to regulatory, biological, and manufacturing hurdles. Rokit's combination of AI-driven bioprinting, robotic delivery, and autologous cell harvesting represents a plausible route to clinical deployment. The kidney regeneration application targets a massive unmet need: chronic kidney disease patients currently face only dialysis and transplantation, both of which are burdensome and limited in supply. If successful, Rokit could open a new frontier in regenerative medicine, but the distance between early-phase safety data and validated therapeutic efficacy is vast. The company's process aligns with the broader trend of additive manufacturing moving into regulated, patient-specific medical applications, though the qualification and regulatory path for bioprinted implants is far more complex than that for metal orthopedic implants or dental aligners.

From a practical standpoint, the coming months will be critical for Rokit Healthcare. The clinical team must demonstrate that the bioprinted omentum patch is reliably produced, surgically deliverable, and safe in a small patient cohort. The use of autologous cells reduces immune rejection risk but introduces manufacturing variability. The company needs to show that its AI-driven bioprinting workflow can produce consistent patches across patients—something that has not been proven at scale in a regulated clinical setting. Success would validate bioprinting as a clinically viable modality; failure would reinforce the sector's reputation for overpromising. The nephrology community will be watching closely.